Moving beyond clinical research, Edges of the Mind explores the deeply personal reality of living with schizophrenia. Written by a dedicated clinician, these stories offer families, patients, and future mental health professionals a unique blend of memory, compassion, and human connection. Discover a different kind of understanding about severe mental illness.

In this blog, Dr. David Pickar reflects on a vital truth modern medicine risks forgetting: the power of bedside observation. Drawing parallels between Dr. Michael Gottlieb’s historic discovery of AIDS and the mid-century breakthroughs in psychiatric medication for schizophrenia, Dr. Pickar argues that while molecular biology and genomics are crucial, they cannot replace the physician paying close attention to the patient in front of them. It is a compelling call to bring the same urgency and careful clinical observation used in the fight against AIDS to the ongoing battle against severe mental illnesses like schizophrenia.

The push to fast-track psychedelics for serious mental illness is understandable, but are these drugs actually ready? A closer look at the recent Executive Order, the reality of FDA approvals, and the medical risks of complex compounds like ibogaine reveals why psychiatry must balance political momentum with rigorous scientific caution.

Can psychedelics treat depression and PTSD? Dr. Pickar shares a cautious perspective on ketamine, MDMA, and the reality of FDA clinical trials.

Discussing a President’s personal characteristics is part and parcel of American democracy. But for a psychiatrist, where does observation end and diagnosis begin? From historical precedents to recent public debates over the mental fitness of our leaders, let's explore why the 1973 Goldwater Rule was created—and whether it still applies today.